CereVasc Revenue and Competitors
Estimated Revenue & Valuation
- CereVasc's estimated annual revenue is currently $5.8M per year.
- CereVasc's estimated revenue per employee is $151,921
- CereVasc's total funding is $114M.
Employee Data
- CereVasc has 38 Employees.
- CereVasc grew their employee count by 90% last year.
CereVasc's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP & Chief Financial Officer | Reveal Email/Phone |
2 | VP, Operations and Engineering | Reveal Email/Phone |
3 | SVP, Operations | Reveal Email/Phone |
4 | Director Operations | Reveal Email/Phone |
5 | Director, Marketing | Reveal Email/Phone |
6 | Operations Manager | Reveal Email/Phone |
CereVasc Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11M | 44 | 13% | N/A | N/A |
#2 | $11M | 44 | 29% | N/A | N/A |
#3 | $4.3M | 17 | 0% | N/A | N/A |
#4 | $3.8M | 15 | -29% | N/A | N/A |
#5 | $5630M | 9122 | -11% | $450M | N/A |
#6 | $4.3M | 17 | 0% | N/A | N/A |
#7 | $4M | 16 | -72% | $23.5M | N/A |
#8 | $44.4M | 177 | 9% | N/A | N/A |
#9 | $45.7M | 182 | 0% | N/A | N/A |
#10 | $15M | 79 | 8% | $105.2M | N/A |
What Is CereVasc?
CereVasc, Inc. is developing the eShuntâ„¢ System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.
keywords:N/A
$114M
Total Funding
38
Number of Employees
$5.8M
Revenue (est)
90%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CereVasc News
Clinical trial underway in Argentina to study minimally invasive treatment for NPH. BOSTON, April 25, 2022 /PRNewswire/ -- CereVasc, Inc.,...
CereVasc, Inc., a Boston, MA-based company focused on improving the treatment of patients with hydrocephalus, closed an expanded Series A financing that raised a total of $43.9m. The round was led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. Led by Dan Levangie, Chair ...
BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. The ...
– Proceeds to fund clinical trials of the eShunt™ System for treatment of hydrocephalus – – Series A financing led by the Perceptive Xontogeny Venture Fund – BOSTON–(BUSINESS WIRE)–June 9, 2020– CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, annou ...
Other Companies in Auburndale
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 50 | -6% | N/A |
#2 | $17.9M | 52 | 16% | N/A |
#3 | $7.8M | 58 | -2% | N/A |
#4 | $11.9M | 60 | 2% | N/A |
#5 | $6.6M | 61 | 15% | N/A |